NASDAQ:PGNX Progenics Pharmaceuticals (PGNX) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$3.94▼$4.7950-Day Range$4.10▼$4.1052-Week Range$1.89▼$6.37Volume34.93 million shsAverage Volume1.16 million shsMarket Capitalization$355.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileFinancialsInstitutional OwnershipOptions ChainSEC FilingsShort InterestSocial MediaProfileFinancialsInstitutional OwnershipOptions ChainSEC FilingsShort InterestSocial Media About Progenics Pharmaceuticals (NASDAQ:PGNX) StockProgenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.Read More PGNX Stock News HeadlinesMarch 3, 2023 | fool.comInvesting in Pharmaceutical StocksFebruary 24, 2023 | benzinga.comDeciphera Pharmaceuticals Stock (NASDAQ:DCPH), Quotes and News SummarySeptember 30, 2023 | Legacy Research (Ad)Elon Did It Again: This Could be Bigger than TeslaLove him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.February 13, 2023 | marketwatch.comOpioid Induced Constipation (OIC) Drug Market Size in 2023 | NEWEST REPORT | Touch New Level in Forthcoming year till 2028February 11, 2023 | finance.yahoo.comInsights on the Flexible Manufacturing Systems for Pharmaceutical Industry Global Market to 2031 - by Product Type, Technology, End-user and RegionJune 19, 2022 | realmoney.thestreet.comI've Got an Options Bandage for a Sick EconomyJanuary 21, 2022 | thestreet.comDow Closes at Record High for 7th Straight Session as Microsoft SurgesOctober 27, 2021 | finance.yahoo.comWhat Falling Estimates & Price Mean for Progenics (PGNX)September 30, 2023 | Legacy Research (Ad)Elon Did It Again: This Could be Bigger than TeslaLove him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.January 19, 2021 | proactiveinvestors.comCytoDyn has multiple shots on goal with its flagship drug Vyrologix to treat for HIV, various cancers and even coronavirusNovember 24, 2020 | businesswire.comLantheus Holdings to Present at the 2020 Evercore ISI HealthCONx ConferenceSeptember 30, 2020 | seekingalpha.comLantheus files U.S. application for PET imaging agent for prostate cancerJuly 30, 2020 | finance.yahoo.comLantheus Holdings Inc (LNTH) Q2 2020 Earnings Call TranscriptJune 22, 2020 | finance.yahoo.comLantheus Completes Merger with ProgenicsJune 16, 2020 | finance.yahoo.comLantheus Stockholders Approve Share Issuance For Merger with ProgenicsJune 16, 2020 | seekingalpha.comLantheus shareholders back stock issuance in Progenics tie-upJune 16, 2020 | finance.yahoo.comProgenics Stockholders Approve Merger with LantheusMay 18, 2020 | finance.yahoo.comProgenics to Present Results from the Phase 3 CONDOR Trial of PyL™ (18F-DCFPyL) in Prostate Cancer at the American Society of Clinical Oncology 2020 Virtual Scientific ProgramMay 8, 2020 | finance.yahoo.comProgenics Class Action: Halper Sadeh LLP Announces Filing Of Shareholder Class Action Lawsuit Against Progenics Pharmaceuticals, Inc.; Investors Are Encouraged To Contact The FirmMay 8, 2020 | finance.yahoo.comEdited Transcript of PGNX earnings conference call or presentation 7-May-20 12:30pm GMTMay 7, 2020 | seekingalpha.comProgenics Pharmaceuticals EPS beats by $0.03, misses on revenueApril 23, 2020 | finance.yahoo.comProgenics Pharmaceuticals Sets First Quarter 2020 Financial Results and Business Update Call for May 7April 14, 2020 | www.marketwatch.comVelan Capital Agrees to Support Merger of Lantheus and ProgenicsApril 14, 2020 | finance.yahoo.comADDING MULTIMEDIA Velan Capital Agrees to Support Merger of Lantheus and ProgenicsMarch 13, 2020 | seekingalpha.comProgenics Pharmaceuticals EPS beats by $0.12, beats on revenueMarch 13, 2020 | finance.yahoo.comPROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTSFebruary 25, 2020 | seekingalpha.comMerger Arbitrage Mondays: Morgan Stanley Acquires E*Trade Financial CorporationSee More Headlines Receive PGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Progenics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PGNX Company Calendar Last Earnings5/07/2020Today9/29/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical Preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:PGNX CUSIP74318710 CIK835887 Webwww.progenics.com Phone646-975-2500FaxN/AEmployees79Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-68,550,000.00 Net Margins-180.28% Pretax MarginN/A Return on Equity-129.46% Return on Assets-53.23% Debt Debt-to-Equity Ratio0.99 Current Ratio2.12 Quick Ratio2.12 Sales & Book Value Annual Sales$34.99 million Price / Sales10.15 Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book7.59Miscellaneous Outstanding Shares86,597,000Free FloatN/AMarket Cap$355.05 million OptionableOptionable Beta1.89 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Mark R. Baker (Age 64)CEO & Director Mr. Patrick Fabbio (Age 51)Exec. VP & CFO Mr. Benedict Osorio (Age 62)Chief Operating Officer Dr. Vivien Wong (Age 62)Exec. VP of Devel. Mr. Bryce V. Tenbarge (Age 46)Sr. VP of Commercial Key CompetitorsIntercept PharmaceuticalsNASDAQ:ICPTLexicon PharmaceuticalsNASDAQ:LXRXVanda PharmaceuticalsNASDAQ:VNDAVerastemNASDAQ:VSTMRigel PharmaceuticalsNASDAQ:RIGLView All Competitors PGNX Stock - Frequently Asked Questions How were Progenics Pharmaceuticals' earnings last quarter? Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) issued its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.03. The biotechnology company had revenue of $6.25 million for the quarter. Progenics Pharmaceuticals had a negative net margin of 180.28% and a negative trailing twelve-month return on equity of 129.46%. Read the conference call transcript. What other stocks do shareholders of Progenics Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Progenics Pharmaceuticals investors own include Vonage (VG), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Caterpillar (CAT), IMAX (IMAX), Novavax (NVAX), Cara Therapeutics (CARA), OPKO Health (OPK), Citius Pharmaceuticals (CTXR) and Dynavax Technologies (DVAX). What is Progenics Pharmaceuticals' stock symbol? Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX." What is Progenics Pharmaceuticals' stock price today? One share of PGNX stock can currently be purchased for approximately $4.10. How much money does Progenics Pharmaceuticals make? Progenics Pharmaceuticals (NASDAQ:PGNX) has a market capitalization of $355.05 million and generates $34.99 million in revenue each year. The biotechnology company earns $-68,550,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. How can I contact Progenics Pharmaceuticals? Progenics Pharmaceuticals' mailing address is ONE WORLD TRADE CENTER 47TH FLOOR, NEW YORK NY, 10007. The official website for the company is www.progenics.com. The biotechnology company can be reached via phone at 646-975-2500 or via email at mdowns@progenics.com. This page (NASDAQ:PGNX) was last updated on 9/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Progenics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.